Search Results

Gotham’s pipeline covers the entire reader-writer-eraser paradigm with three lead programs advancing in parallel through preclinical discovery

Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, today announced the appointment of Carlo Incerti, M.D., Ph.D. as an independent Board Member.

Gotham is developing a novel drug class targeting RNA-modifying proteins

Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.

On the banks of Providence’s Woonasquatucket River, Rhode Island Governor Gina M. Raimondo, Providence Mayor Jorge O. Elorza, Rhode Island Commerce Secretary Stefan Pryor, and community leaders joined Viraj Puri, co-founder and CEO of Gotham Greens, to officially announce and preview construction progress on the company’s 110,000 square foot state-of-the-art greenhouse farm that will create approximately 60 permanent and 100 construction jobs.

The investment firm, known for its financial support of some of the most reputable cannabis companies in the industry, is the first institutional investment in the company.

Versant-seeded company translating insights about RNA-modifying protein targets into drug candidates

Completion of Gene-to-Lead phase for first discovery project targeting METTL3/METTL14 complex.

Research led to a collection of over 2,000 analogues and over 80 distinct chemotypes displaying an up to 1,000-fold increased affinity to epitranscriptomic targets.